AADI - Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors

• Preclinical data showed that combining Aadi Bioscience's ( NASDAQ: AADI ) Fyarro (nab-sirolimus) with a KRAS inhibitor led to improved anti-tumor activity .
• KRAS is frequently mutated in non-small cell lung cancer (NSCLC) and other tumors.
• The company's research looked at KRAS inhibitors Lumakras (sotorasib) or adagrasib, the latter under development by Mirati Therapeutics ( MRTX ) in combination with Fyarro or Afinitor (everolimus).
• Fyarro is already approved for approved for the treatment of locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor.
• Results will be presented at the EORTC-NCI-AACR Symposium later this month.
• Check out why Seeking Alpha contributor Jonathan Faison is bullish on Aadi Bioscience ( AADI ).

For further details see: